Primer: AgomAb Therapeutics (AGMB US) - Aug 2026
AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic and inflammatory diseases, with...
93 Views
𝛼SK or SearchENTITY
AgomAb Therapeutics (AGMB US)
AgomAb Therapeutics (AGMB US)
9
Analysis
Health Care • Belgium
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications. The company's pipeline includes small molecule and antibody product candidates, such as Ontunisertib (AGMB-129) for Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.
morex